drugset / Trial / NCT02150928

An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)

NCT02150928

Phase 2 Withdrawn Jazz Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the serum asparaginase activity in subjects ages 18 to \<40 years with ALL or LBL who have developed a hypersensitivity to native E. coli asparaginase or pegaspargase.

Timeline

Start
2014-05
Primary completion
2015-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Asparaginase Erwinia chrysanthemi Protein / enzyme biologic 25000 unknown Intramuscular